Key Takeaways
- Shares of Novo Nordisk rose over 6% following the FDA’s proposal to eliminate semaglutide, tirzepatide, and liraglutide from the 503B bulks compounding list
- The regulatory agency determined outsourcing facilities have no clinical justification for compounding these medications
- Stakeholders have until June 29, 2026, to submit comments during the public feedback period before final regulatory action
- The Danish pharmaceutical company topped the Copenhagen exchange Thursday, reaching levels unseen since early March
- Year-to-date performance shows a decline exceeding 16% despite Thursday’s significant rally
Shares of Novo Nordisk advanced more than 6% Thursday following the FDA’s announcement of proposed restrictions on weight-loss drug compounding, a regulatory shift that stands to strengthen the Danish pharmaceutical company’s market position.
The federal agency put forward a proposal to eliminate semaglutide, tirzepatide, and liraglutide from the 503B bulks list. According to the FDA’s assessment, outsourcing facilities lack clinical justification for producing compounded versions of these treatments.
The pharmaceutical giant led the Copenhagen stock exchange Thursday, with shares reaching their strongest position in over sixty days.
NVO was changing hands near $42.38 during recent trading, significantly above both its 20-day moving average of $39.03 and its 50-day moving average of $38.87.
Thursday’s rally still leaves the stock trading beneath its 200-day moving average of $50.32, with year-to-date losses exceeding 16%.
The FDA established a public comment window extending through June 29, 2026, allowing stakeholders to weigh in before the agency issues its final determination.
Recent Challenges for the Pharmaceutical Giant
Novo Nordisk has navigated several obstacles in recent months. Canadian health authorities granted approval for the first generic alternative to Ozempic, introducing competitive pressure in a significant market.
The company responded by initiating a share repurchase initiative. Management has acquired approximately 13.4 million B-shares valued at 3.44 billion Danish kroner since February 2026, executing part of a 15 billion kroner program spanning twelve months.
Regarding development efforts, the pharmaceutical company commenced a Phase 3 clinical study for a knee osteoarthritis therapy while securing FDA fast-track status for a cardiovascular treatment.
First quarter 2026 financial results are scheduled for release on May 6.
Technical Analysis Perspective
Near-term momentum indicators show positive signals. The MACD has generated a buy signal while the RSI registers 54.73, indicating moderately bullish conditions.
The ADX measurement of 17.26 reveals limited trend strength. Meanwhile, the Stochastic RSI has triggered a sell signal, highlighting potentially overbought territory.
Anton Kharitonov from Traders Union highlighted the delicate technical structure, noting that weak momentum readings combined with overbought conditions could quickly drain buying pressure. He identified the generic Ozempic approval in Canada as an additional risk factor.
Viktoras Karapetjanc, another analyst from Traders Union, maintains a more optimistic perspective. He views the repurchase program and robust clinical development efforts as foundations for sustained value, characterizing the recent decline as a possible springboard for future gains.
Strategist Jainam Mehta identified a tactical trading zone between $40.78 and $43.23 as the critical area to monitor. According to his analysis, a convincing move beyond either boundary would be necessary to shift the immediate risk outlook.
Shares opened Thursday with a gap higher of approximately $0.37 and added $1.94, representing a 4.80% intraday advance. Volatility during the session measured 2.47%.
